2020 American Transplant Congress
Pharmacokinetic Evaluation of a De Novo Envarsus XR® (tacrolimus Extended Release) Dosing Strategy in Kidney Transplant Recipients
*Purpose: Envarsus XR® is a once-daily tablet formulation of tacrolimus recently approved for the prophylaxis of organ rejection in de novo kidney transplant recipients (KTx).…2020 American Transplant Congress
Influence of HLA Compatibility on Cytomegalovirus Infection Post-Kidney Transplantation
*Purpose: Cytomegalovirus (CMV) infection after kidney transplantation is associated with a high morbidity and higher risk of graft loss. A latent Human CMV infection can…2020 American Transplant Congress
Bypassing the Nearest Transplant Center for Care is Associated with Gains in Time to Living Donor but Not Deceased Donor Kidney Transplantation or Improved Graft Outcomes
*Purpose: Some patients may gain an advantage if they choose to bypass their local transplant center and receive care at a center further away but…2020 American Transplant Congress
Endoscopic Injection Therapy for Vesicoureteral Reflux after Kidney Transplantation
Urology and Kidney Transplant Surgery, Sapporo City General Hospital, Sapporo, Sapporo, Japan
*Purpose: Vesicoureteral reflux (VUR) in a kidney graft is a complication of post kidney transplantation (KT) causing recurrent upper urinary tract infection and consequent kidney…2020 American Transplant Congress
Belatacept Combined with BTLA Prolong Allogeneic Kidney Graft Survival and Inhibited Acute Rejection after Kidney Transplantation
Jiangsu Province Hospital, Nanjing, China
*Purpose: Belatacept as a high-affinity variant of CTLA-4Ig, has been applied into kidney transplantation to against acute rejection. However, adoption of Belatacept has been limited…2020 American Transplant Congress
Alemtuzumab and Associated Infectious and Transplant Outcomes in Renal Re-Transplant Patients
The Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC
*Purpose: The purpose of this study was to evaluate infectious and transplant outcomes exclusively in renal re-transplant patients who had received alemtuzumab for induction therapy.*Methods:…2020 American Transplant Congress
The Eplet-Mismatch Landscape in Kidney Patients and Deceased Donors in British Columbia
*Purpose: Minimizing quantitative donor/recipient mismatch at the HLA epitope level may optimize graft outcomes in renal transplantation, but the degree to which optimal matching can…2020 American Transplant Congress
Risk Factors for Adverse Clinical Outcomes amongst Renal Transplant Candidates Undergoing Screening Angiography for Coronary Artery Disease
*Purpose: Patient’s with ESRD undergoing evaluation for kidney transplantation routinely undergo screening for coronary artery disease (CAD). Screening recommendations in this population differ between ACC/AHA…2020 American Transplant Congress
CD38 Antibody Daratumumab for the Treatment of Chronic Antibody-Mediated Kidney Allograft Rejection
*Purpose: Late antibody-mediated rejection (ABMR) is a major cause of transplant failure. Potential therapeutic targets are plasma cells (PC) and natural killer (NK) cells expressing…2020 American Transplant Congress
Frailty and Its Implications for Early Post-Transplant Outcomes in Kidney Transplant Recipients
Toronto General Hospital, Toronto, ON, Canada
*Purpose: Frailty, a measure of physiologic reserve, is associated with poor early outcomes, like early hospital readmission (EHR) and delayed-graft function (DGF) in kidney transplant…
- « Previous Page
- 1
- …
- 132
- 133
- 134
- 135
- 136
- …
- 531
- Next Page »
